Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratect 5% as adjuvant therapy in pemphigus vulgaris
2013-000211-24Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pemphigus vulgaris (PV) comparing Intratect adjuvant therapy with Placebo adjuvant therapy (2 arms). Primary endpoint: Relapse rate on therapy. Started Jul 2013; status: terminated.
02
Drugs
IgPro10
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2013-000211-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000211-24.